Martin Jovana Y, Goff Barbara A, Urban Renata R
Division of Gynecologic Oncology, University of Washington Medical Center, Seattle, WA, United States.
Division of Gynecologic Oncology, University of Washington Medical Center, Seattle, WA, United States.
Gynecol Oncol. 2016 Sep;142(3):471-6. doi: 10.1016/j.ygyno.2016.06.018. Epub 2016 Jul 4.
To determine if preoperative hyponatremia in women with ovarian, fallopian tube (FT), and primary peritoneal cancers (PPC) is associated with postoperative complications.
We performed a retrospective population-based cohort study of women with a postoperative diagnosis of ovarian, FT, or PPC who had a cytoreductive procedure in the National Surgical Quality Improvement Program (NSQIP) database from 2005 to 2013. The primary exposure, preoperative sodium, was classified as normal (135mEq/L-142mEq/L) or hyponatremic (≤134mEq/L). Where appropriate, preoperative characteristics were compared with Chi-squared or Fisher's exact tests. Multivariate logistic regression was used to determine adjusted odds ratios (aOR) with 95% confidence intervals (CI).
4009 subjects met inclusion criteria. Thirty day mortality was higher in the hyponatremic group compared to the normal serum sodium group (3.56% vs 1.18%). When patients of any age were noted to have at least two pertinent preoperative lab abnormalities, including hyponatremia, there was an increased risk of postoperative complications for patients over the age of 65 (Table 3). After adjusting for serum albumin and other confounders, preoperative hyponatremia was associated with an increased risk of hospital stay of >14days (aOR 1.69; 95% CI 1.11-2.57) and 30day postoperative mortality (aOR 2.37; 95% CI 1.13-4.98).
Hyponatremia is associated with postoperative 30day mortality and morbidity in women with ovarian, FT, and PPC. Serum sodium in conjunction with other markers may have the potential to identify candidates for neoadjuvant chemotherapy. Additional work is needed to determine if correction of hyponatremia in the preoperative period alters outcomes.
确定卵巢癌、输卵管癌(FT)和原发性腹膜癌(PPC)女性患者术前低钠血症是否与术后并发症相关。
我们对2005年至2013年在国家外科质量改进计划(NSQIP)数据库中接受了细胞减灭术且术后诊断为卵巢癌、FT或PPC的女性患者进行了一项基于人群的回顾性队列研究。主要暴露因素,即术前钠水平,分为正常(135mEq/L - 142mEq/L)或低钠血症(≤134mEq/L)。在适当情况下,术前特征采用卡方检验或费舍尔精确检验进行比较。多因素逻辑回归用于确定调整后的优势比(aOR)及95%置信区间(CI)。
4009名受试者符合纳入标准。低钠血症组的30天死亡率高于正常血清钠组(3.56%对1.18%)。当任何年龄的患者术前至少有两项相关实验室异常,包括低钠血症时,65岁以上患者术后并发症风险增加(表3)。在调整血清白蛋白和其他混杂因素后,术前低钠血症与住院时间>14天(aOR 1.69;95% CI 1.11 - 2.57)及术后30天死亡率(aOR 2.37;95% CI 1.13 - 4.98)的风险增加相关。
低钠血症与卵巢癌、FT和PPC女性患者术后30天死亡率及发病率相关。血清钠与其他标志物结合可能有潜力识别新辅助化疗的候选者。需要进一步研究以确定术前纠正低钠血症是否会改变预后。